Stockreport

Beam Therapeutics (BEAM): Assessing Valuation After Strategic Shift and Analyst Optimism on BEAM-302 Program [Yahoo! Finance]

Beam Therapeutics Inc.  (BEAM) 
PDF The spotlight is on the company's BEAM-302 DNA editing program, with management signaling strong confidence in its technological advantages over competing approaches. In [Read more]